The Complete® SE SFA Study for the Treatment of SFA/PPA Lesions

Completed · Not applicable

Conditions studied: Peripheral Vascular Disease

In brief

To evaluate the safety and efficacy of the Complete SE SFA Stent System in the treatment of de novo and/or restenotic lesions or occlusions in the Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) in subjects with symptomatic Peripheral Artery Disease (PAD).

Key facts

Study ID

NCT00814970

Run by

Medtronic Endovascular

People needed

196

Starts

2008-11-01

Expected to finish

2013-12-01

Last updated by the study team

2016-04-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Rutherford 2-4, with an occlusion or de novo and/or restenotic SFA/PPA lesion ≥50% and ankle-brachial index/toe-brachial index (ABI/TBI) <0.90/0.80.
• Target lesion located at least 1 cm distal to the take-off of the profunda femoris artery and at least 3 cm proximal to the highest point of the cortical margin of the femur;
• Target vessel reference diameter is ≥4.0 mm and ≤7.0 mm (visual estimate);
• Target lesion length is ≥4.0 cm and ≤14.0 cm (visual estimate);
• Adequate distal run-off to the ankle in the target limb (defined as having at least one patent calf vessel <50% stenosed;
• Life expectancy >12 months.

You may not qualify if…

• Women who do not have a negative serum or urine pregnancy test documented within 7 days prior to enrollment;
• Any condition that precludes safe access with percutaneous transluminal angioplasty (PTA) devices, such as: excessive peripheral artery disease, unresolved fresh thrombus in the target lesion/vessel, or a target lesion/vessel that is excessively tortuous or calcified;
• Lesions in contralateral SFA/PPA that require intervention during the index procedure, or within 30 days before or after the index procedure;
• Previous treatment to the target lesion within the 3 months prior to enrollment; previous femoropopliteal bypass in target vessel; previous stenting of the target lesion;
• Target lesion located within an aneurysm or associated with an aneurysm in the vessel segment either proximal or distal to the target lesion;
• Target lesion requires treatment other than standard PTA prior to stent placement (i.e., no other devices or procedures such as cutting balloons and laser atherectomy are permitted to be used during the index procedure);
• History of bleeding diatheses or coagulopathy or will refuse blood transfusions;
• Known impaired renal function, defined as creatinine >2.5 mg/dl;
• Known platelet count <80,000 cells/mm3 or >700,000 cells/mm3;
• Known white blood cell (WBC) of <3,000 cells/mm3;
• Participation in another investigational device or drug study and has not completed the primary endpoint(s) or which clinically interferes with the Complete SE SFA Study endpoints, or previously enrolled in the Complete SE SFA Study.

Where it is running

• Washington Hospital — Fremont, California, United States
• N. Florida Regional Medical Center — Gainesville, Florida, United States
• Munroe Regional Medical Center — Ocala, Florida, United States
• AnMed Health — Anderson, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.